MedTrace Logo

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV

NCT00802854 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 244

Last updated 2018-11-21

Study results available
· View outcomes & findings →

Summary

The objective of this study is to collect the safety and efficacy data of Eraxis IV (anidulafungin) 100 mg according to Korea Ministry of Food and Drug Safety regulations.

Conditions

  • Candidemia
  • Other Forms of Candida Infections(Intra-abdominal Abscess, Peritonitis)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-02
Primary Completion
2016-05-20
Completion
2016-05-20

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00802854 on ClinicalTrials.gov